Efficacy Of Sodium Glucose Transporter Inhibitor (SGLT2I) In Adult Patients With Congenital Heart Disease

This study is testing a medication called an SGLT2 inhibitor (the brand name Jardiance is mentioned) in adults with congenital heart disease — heart defects present from birth — who are experiencing a decline in their heart's pumping function. SGLT2 inhibitors have shown heart benefits in other populations, and this trial tests whether they help in congenital heart disease. **You may be eligible if...** - You are 18 or older - You have congenital heart disease (a heart condition you were born with) - Your heart pumping function has recently declined (ejection fraction below 60% and dropped more than 5% in the last 6 months) - Your heart defect is of moderate or complex structural type - You can complete computer-based mental assessments **You may NOT be eligible if...** - You have been diagnosed with diabetes - You have a contraindication to Jardiance or related heart failure medications - Your kidney function is very poor (GFR below 20) - You are pregnant, breastfeeding, or planning pregnancy within the next year - You have liver disease, or certain rare metabolic or enzyme disorders Talk to your doctor to see if this trial is right for you.